Skip to main content
SpringerLink
Log in

Pathology and Staging

  • Chapter
  • First Online:
A Guide to Management of Urological Cancers

  • 192 Accesses

Abstract

This chapter provides an overview of current concepts in etiopathogenesis, molecular alterations and diagnostic and reporting guidelines in prostatic carcinoma which is the second most common cancer in men. Acinar adenocarcinoma has been detailed with respect to its subtypes, grading and staging. Emphasis has been given on descriptions of Gleason score and group grades which form an important prognostic parameter in acinar adenocarcinoma. High-grade prostatic intraepithelial neoplasia and intraductal carcinoma of prostate need to be recognized as separate entities owing to therapeutic and prognostic implications. Neuroendocrine tumours of the prostate represent a considerable chunk of prostatic tumours, and their full spectrum has been outlined in detail. Evolving and established genomic markers have a role in genetic risk assessment, prognostication and providing therapeutic options in prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020.

    Google Scholar 

  2. Smith SC. General concepts, prostate carcinoma. In: Amin MB, Tickoo SK, editors. Diagnostic pathology: genitourinary. 2nd ed. Salt Lake City, UT: Elsevier; 2016. p. 600–7.

    Google Scholar 

  3. Kench JG, Kristiansen G, Berney DM, et al. Acinar adenocarcinoma. In: WHO Classification of Tumours Editorial Board, editor. Urinary and male genital tumours, WHO classification of tumours series, vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

    Google Scholar 

  4. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41(6):781–93. https://doi.org/10.1016/j.humpath.2010.02.011.

    Article  PubMed  Google Scholar 

  5. Rosoff JS, Prasad SM, Savage SJ. Ultrasonography in prostate cancer: current roles and potential applications in radiorecurrent disease. World J Urol. 2013;31(6):1353–9. https://doi.org/10.1007/s00345-013-1080-9.

    Article  CAS  PubMed  Google Scholar 

  6. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52. https://doi.org/10.1097/PAS.0000000000000530.

    Article  PubMed  Google Scholar 

  7. van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litjens G, McKenney JK, Melamed J, Mottet N, Paner GP, Samaratunga H, Schoots IG, Simko JP, Tsuzuki T, Varma M, Warren AY, Wheeler TM, Williamson SR, Iczkowski KA, ISUP Grading Workshop Panel Members. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44(8):e87–99. https://doi.org/10.1097/PAS.0000000000001497.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175(3 Pt 1):820–34. https://doi.org/10.1016/S0022-5347(05)00337-X.

    Article  PubMed  Google Scholar 

  9. Al-Ahmadie H. Prostatic intraepithelial neoplasia. In: Amin MB, Tickoo SK, editors. Diagnostic pathology: genitourinary. 2nd ed. Salt Lake City, UT: Elsevier; 2016. p. 590–9.

    Google Scholar 

  10. Netto GJ, Humphrey PA, Galluzzi CM. High-grade prostatic intraepithelial neoplasia. In: WHO Classification of Tumours Editorial Board, editor. Urinary and male genital tumours, WHO classification of tumours series, vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

    Google Scholar 

  11. Singh PB, Nicholson CM, Ragavan N, Blades RA, Martin FL, Matanhelia SS. Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience. BMC Urol. 2009;9:3. https://doi.org/10.1186/1471-2490-9-3.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19:1528–35.

    Article  PubMed  Google Scholar 

  13. Epstein JI, Oxley J, Ro JY, Van der Kwast T, Zhou M. lntraductal carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary system and male genital organs, 2016. 4th ed. Lyon: International Agency for Research on Cancer; 2016.

    Google Scholar 

  14. Wobker SE, Epstein JI. Differential diagnosis of Intraductal lesions of the prostate. Am J Surg Pathol. 2016;40(6):e67–82. https://doi.org/10.1097/PAS.0000000000000609.

    Article  PubMed  Google Scholar 

  15. Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA. Systematic review links the prevalence of Intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol. 2017;72(4):492–5. https://doi.org/10.1016/j.eururo.2017.03.013.

    Article  PubMed  Google Scholar 

  16. Kwast THVD, Kristiansen G, McKenney JK. Ductal adenocarcinoma. In: WHO Classification of Tumours Editorial Board, editor. Urinary and male genital tumours, WHO classification of tumours series, vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

    Google Scholar 

  17. Rubin MA. Treatment-related neuroendocrine prostatic carcinoma. In: WHO Classification of Tumours Editorial Board, editor. Urinary and male genital tumours, WHO classification of tumours series, vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

    Google Scholar 

  18. Klein EA, Kupelian PA, Witte JS. Does a family history of prostate cancer result in more aggressive disease? Prostate Cancer Prostatic Dis. 1998;16:297–300.

    Article  Google Scholar 

  19. Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R. Prostate cancer Germline variations and implications for screening and treatment. Cold Spring Harb Perspect Med. 2018;8(9):a030379. https://doi.org/10.1101/cshperspect.a030379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA. 1997;27815:1251–5.

    Article  Google Scholar 

  21. Ni Raghallaigh H, Eeles R. Genetic predisposition to prostate cancer: an update. Familial Cancer. 2022;21:101–14. https://doi.org/10.1007/s10689-021-00227-3.

    Article  PubMed  Google Scholar 

  22. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;3589:910–9.

    Article  Google Scholar 

  23. Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, et al. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol. 2019;751:184–92.

    Article  Google Scholar 

  24. Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O’Leary E, Esplin ED, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;54:523–8.

    Article  Google Scholar 

  25. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, et al. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019. J Clin Oncol. 2020;38:2798–811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cucchiara V, Cooperberg MR, Dall’Era M, et al. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73(4):572–82. https://doi.org/10.1016/j.eururo.2017.10.036.

    Article  PubMed  Google Scholar 

  27. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–38. https://doi.org/10.1056/NEJMoa1315815.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hempelmann JA, Lockwood CM, Konnick EQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer. 2018;6(1):29. https://doi.org/10.1186/s40425-018-0341-y.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. I. Molecular biomarkers in prostate cancer. Am J Surg Pathol. 2020;44(7):e15–29. https://doi.org/10.1097/PAS.0000000000001450.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Dr. Meenakshi Kamboj, Dr. Divya Bansal and Dr. Ankur Kumar for their assistance in the preparation of this manuscript.

Declaration

The authors declare that no funds, grants or other supports were received during the preparation of this manuscript.

The authors declare that they have no conflict of interest.

The authors have no relevant financial or non-financial interests to disclose.

Author information

Authors and Affiliations

  1. Department of Molecular Biology, Amrita Medical Institute & Research Centre, Faridabad, India

    Moushumi Suryavanshi & Garima Durga

  2. Department of Lab services, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India

    Garima Durga

Authors
  1. Moushumi Suryavanshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Garima Durga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Prabhjot Singh

  2. Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Brusabhanu Nayak

  3. Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Sridhar Panaiyadiyan

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Suryavanshi, M., Durga, G. (2023). Pathology and Staging. In: Singh, P., Nayak, B., Panaiyadiyan, S. (eds) A Guide to Management of Urological Cancers. Springer, Singapore. https://doi.org/10.1007/978-981-99-2341-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-2341-0_15

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-2340-3

  • Online ISBN: 978-981-99-2341-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation